Looming Patent Deadline Pushes Sanofi (France) To Be More Aggressive; Wants To Add Oral GLP-1 To Diabetes Offering

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sanofi (SAN) wants to add an oral diabetes drug that mimics a hormone known as GLP-1 as the French drugmaker seeks to lower its reliance on the blockbuster Lantus insulin, set to lose patent protection soon.

“It’s one of our strategic interests,” Pierre Chancel, who heads Sanofi’s diabetes unit, said in an interview in Vienna, where he is attending the European Association for the Study of Diabetes conference. Paris-based Sanofi has a “very early stage” experimental oral GLP-1 product in its pipeline and will also be looking at external candidates, Chancel said.

Help employers find you! Check out all the jobs and post your resume.

Back to news